icon

Sustainable Weight Loss

Achieve lasting results with 12-15% average weight loss maintained over time

Cardiovascular Protection

Reduces risk of major cardiovascular events by 20%

Multiple Forms Available

Choose between weekly injection or daily oral tablet for your lifestyle

Why Semaglutide is Your Weight Loss Solution

Semaglutide is a groundbreaking glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized weight management and diabetes treatment. Originally developed for type 2 diabetes, its remarkable weight loss effects have made it the go-to choice for sustainable, medically-supervised weight management.

Patient Success Story: "After struggling with weight for years, Semaglutide finally gave me the control I needed. I've lost 38 pounds and kept it off for over a year." - Michael R.

Mechanism of Action

  • Insulin Secretion: Stimulates glucose-dependent insulin release from pancreatic beta cells
  • Glucagon Suppression: Reduces glucagon secretion from pancreatic alpha cells when glucose levels are elevated
  • Gastric Emptying: Slows gastric emptying, promoting satiety and reducing post-meal glucose spikes
  • Central Appetite Control: Acts on hypothalamic receptors to reduce appetite and food intake
  • Beta Cell Preservation: May help preserve pancreatic beta cell function

Life-Changing Benefits

Diabetes Benefits:

  • HbA1c reduction of 1.0-1.8%
  • Reduced fasting glucose levels
  • Lower postprandial glucose excursions
  • Cardiovascular risk reduction
  • Low hypoglycemia risk

Weight Management Success:

  • Average weight loss of 12-15% in clinical trials
  • Sustained weight reduction over 68 weeks
  • Improved body composition
  • Reduced visceral adiposity
  • Better weight maintenance
Clinical Excellence: The STEP clinical trial program demonstrated that 86% of patients achieved at least 5% weight loss, with many achieving transformational results of 15% or more.

Dosing and Administration

Injectable Form:

Route: Subcutaneous injection once weekly

Starting Dose: 0.25 mg once weekly for 4 weeks

Dose Escalation:

  • 0.5 mg once weekly (weeks 5-8)
  • 1.0 mg once weekly (maintenance for diabetes)
  • 1.7 mg once weekly
  • 2.4 mg once weekly (weight management dose)

Oral Form:

Route: Oral tablet once daily

Starting Dose: 3 mg once daily for 30 days

Maintenance: 7 mg or 14 mg once daily

Administration: Take on empty stomach with ≤4 oz water, 30 minutes before first food/drink/medication of the day

Side Effects

Common (≥5%):

  • Nausea (15-20%)
  • Vomiting (5-9%)
  • Diarrhea (8-9%)
  • Abdominal pain (5-7%)
  • Constipation (3-7%)
  • Headache (5-6%)
  • Fatigue (3-5%)

Serious (Rare):

  • Acute pancreatitis
  • Gallbladder disease
  • Acute kidney injury
  • Diabetic retinopathy complications
  • Severe hypoglycemia (with insulin/sulfonylureas)
  • Thyroid C-cell tumors (animal studies)

Drug Interactions

  • Insulin and Insulin Secretagogues: Increased risk of hypoglycemia; dose reduction may be needed
  • Oral Medications: May delay absorption due to delayed gastric emptying
  • Warfarin: Monitor INR more frequently when initiating semaglutide
  • Oral Contraceptives: Use alternative contraceptive method for 4 weeks after starting or dose increases

Monitoring Parameters

  • Blood Glucose: Regular monitoring, especially when combined with other diabetes medications
  • HbA1c: Every 3-6 months
  • Weight and BMI: Regular monitoring for weight management indication
  • Renal Function: Baseline and periodic monitoring
  • Signs of Pancreatitis: Educate patients on symptoms
  • Diabetic Retinopathy: Regular ophthalmologic examinations

Telehealth Consultation Form

FormCRM